TY - JOUR
T1 - Multi-center study
T2 - The biochemical efficacy, safety and tolerability of a new α1-proteinase inhibitor, Zemaira
AU - Stocks, James M.
AU - Brantly, Mark
AU - Pollock, David
AU - Barker, Alan
AU - Kueppers, Friedrich
AU - Strange, Charlie
AU - Donohue, James F.
AU - Sandhaus, Robert
N1 - Funding Information:
This research was fully funded by ZLB Behring LLC. Keywords: α1-antitrypsin deficiency, Proteinase inhibitor, Efficacy, Safety. Correspondence to: Dr. J. M. Stocks The University of Texas Health Center at Tyler 11937 US Hwy 271 Tyler TX 75708-3154, USA email: c/o Debbie.fielder@uthct.edu
PY - 2006
Y1 - 2006
N2 - Augmentation therapy with a plasma derived α1-Proteinase Inhibitor (α1-PI) has been demonstrated to be effective in restoring serum Alpha1-antitrypsin (AAT)* levels in individuals with AAT Deficiency (note: α1 PI and AAT are synonymous). The objective of this study was to demonstrate that the steady-state trough serum α1-PI levels, achieved by a new plasma derived α1-PI (Zemaira, study drug, ZLB Behring LLC, King of Prussia, Pennsylvania, USA), were bioequivalent to those achieved by the currently available α1-PI therapy, Prolastin (control drug, Bayer Corporation, Berkeley, California, USA), and maintained weekly trough serum antigenic α1-PI levels above the protective threshold of 11 μM. This multi-center, controlled study randomized a total of 44 subjects to receive either study or control drug for a 10-week double-blind phase. The control group was then crossed over to receive the study drug for the remainder of the study (14 weeks). The difference in mean trough serum antigenic α1-PI level between the treatment groups was 1.45 μM (90% CI-2.77, -0.13), signifying bioequivalence. The mean trough serum antigenic α1-PI level in the study drug group was greater than the therapeutic threshold of 11 μM, achieving a level of 17.7 μM during the steady-state period. Treatment-related adverse events (AEs) were seen in 7% and 21% of study and control drug treated subjects, respectively. No documented viral transmission occurred. These results demonstrate that the new plasma derived α1-PI (Zemaira) is bioequivalent to the currently available product Prolastin, is well tolerated, and safe with respect to the risk of viral transmission.
AB - Augmentation therapy with a plasma derived α1-Proteinase Inhibitor (α1-PI) has been demonstrated to be effective in restoring serum Alpha1-antitrypsin (AAT)* levels in individuals with AAT Deficiency (note: α1 PI and AAT are synonymous). The objective of this study was to demonstrate that the steady-state trough serum α1-PI levels, achieved by a new plasma derived α1-PI (Zemaira, study drug, ZLB Behring LLC, King of Prussia, Pennsylvania, USA), were bioequivalent to those achieved by the currently available α1-PI therapy, Prolastin (control drug, Bayer Corporation, Berkeley, California, USA), and maintained weekly trough serum antigenic α1-PI levels above the protective threshold of 11 μM. This multi-center, controlled study randomized a total of 44 subjects to receive either study or control drug for a 10-week double-blind phase. The control group was then crossed over to receive the study drug for the remainder of the study (14 weeks). The difference in mean trough serum antigenic α1-PI level between the treatment groups was 1.45 μM (90% CI-2.77, -0.13), signifying bioequivalence. The mean trough serum antigenic α1-PI level in the study drug group was greater than the therapeutic threshold of 11 μM, achieving a level of 17.7 μM during the steady-state period. Treatment-related adverse events (AEs) were seen in 7% and 21% of study and control drug treated subjects, respectively. No documented viral transmission occurred. These results demonstrate that the new plasma derived α1-PI (Zemaira) is bioequivalent to the currently available product Prolastin, is well tolerated, and safe with respect to the risk of viral transmission.
KW - Efficacy
KW - Proteinase inhibitor
KW - Safety
KW - α-antitrypsin deficiency
UR - http://www.scopus.com/inward/record.url?scp=33745032125&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745032125&partnerID=8YFLogxK
U2 - 10.1080/15412550500493220
DO - 10.1080/15412550500493220
M3 - Article
C2 - 17175661
AN - SCOPUS:33745032125
SN - 1541-2555
VL - 3
SP - 17
EP - 23
JO - COPD: Journal of Chronic Obstructive Pulmonary Disease
JF - COPD: Journal of Chronic Obstructive Pulmonary Disease
IS - 1
ER -